Want to evaluate oncology drugs in patient tumors with preserved native TME? Discover the benefits of the 3D Ex Vivo Patient Tissue Platform in our Webinar.
Patient-relevant translational systems that better mimic the heterogeneity and molecular/genetic complexity of human tumors to:
In this webinar Dr. Nataliia Beztsinna reviews a 3D high content imaging-based screening assay for evaluating monotherapy and combination drug responses in patient tumors with endogenous immune cell populations intact.
Dr. Nataliia Beztsinna joined OcellO (now Crown Bioscience Netherlands) in 2018 as Senior Scientist in Immuno-Oncology team. Since 2020 she is leading the efforts in 3D Ex vivo Patient Tissue Platform that is designed to evaluate preclinical drug candidates in ultrafresh tumor material from patients. Her expertise is in assay development for oncology and immuno-oncology drugs testing in ex vivo 3D tumor tissues with preservation of their native TME and with help of 3D high content image analysis. Dr. Beztsinna obtained her PhD in Biochemistry at the University of Bordeaux and continued her post-doctoral studies in Pharmaceutics at Utrecht and Leiden Universities.